LA JOLLA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that Bruce Steel, Equillium’s President and Chief Business Officer, will present at two upcoming investor conferences in November 2018.
|Stifel 2018 Healthcare Conference |
Tuesday, Nov. 13, 2018
5:00 p.m. ET
New York, NY
|Jefferies 2018 London Healthcare Conference |
Thursday, Nov. 15, 2018
8:00 a.m. GMT
London, United Kingdom
Live webcasts of both presentations will be available under the Investors section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic. For more information, visit www.equilliumbio.com.
LifeSci Advisors, LLC
Heidi Chokeir, Ph.D.